Weight loss drugs linked to metabolic rebound and eating disorder risks

The rising use of GLP-1 medications, such as semaglutide and tirzepatide, for rapid weight loss has brought significant health concerns to light. While these drugs can lead to weight reductions of 14% to 20% over 72 weeks, medical experts warn of a severe rebound effect. Without permanent lifestyle changes, patients may regain approximately 60% of lost weight within a year of stopping treatment, often at a rate four times faster than conventional dieting. This weight regain is frequently accompanied by the return of metabolic issues and hypertension.

Beyond the physiological rebound, the trend is linked to broader psychological risks. The World Health Organization reported that 16 million people suffered from eating disorders in 2021. In Argentina, between 10% and 15% of the population has reported experiencing an eating disorder, with women making up 90% of cases. Medical professionals note that since the pandemic, consultations for eating disorders have increased by 70%, driven by social media pressure and increased screen time, creating a fertile environment for disordered eating behaviors.